Update on the management and treatment of viral hepatitis

doi:10.3748/wjg.v27.i23.3249

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7923)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

662

WORD

192

HTML

5785

Figures (1-1)

249

Tables (1-1)

147

Sum=7035

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

359

Download

529

Sum=888

Jun 21, 2021 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jun 21, 2021; 27(23): 3249-3261
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3249

Open in New Tab Full Size Figure Download Figure

Figure 1 Diagrammatic summary of the therapeutic options targeting covalently closed circular deoxyribonucleic acid to prevent hepatitis B virus persistence. After entering the cell, the virion is uncoated and the relaxed circular deoxyribonucleic acid (DNA) genome (rcDNA) translocates into the cell nucleus. Once there, the covalently closed circular DNA (cccDNA) formed resides in the nucleus of infected cells as a minichromosome and originate the new viruses. Drugs that prevent cccDNA formation, that affect its stability, or even cccDNA activity must stop hepatitis B virus persistence. cccDNA: covalently closed circular deoxyribonucleic acid; HBV: Hepatitis B virus; RNA: Ribonucleic acid.

Citation: Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261
URL: https://www.wjgnet.com/1007-9327/full/v27/i23/3249.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i23.3249